{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:51:23Z","timestamp":1786989083546,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.farma.2024.04.023","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:33:25Z","timestamp":1718152405000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis"],"prefix":"10.1016","volume":"49","author":[{"given":"Clara","family":"Cortell-Fuster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Amparo","family":"Mart\u00ednez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Cerc\u00f3s-Lleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Climente-Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"D\u00edaz-Corpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Mateu-Puchades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Revert-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9639","key":"10.1016\/j.farma.2024.04.023_bb0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.farma.2024.04.023_bb0010","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pediatrneurol.2003.09.002","article-title":"Tuberous sclerosis complex: genetics to pathogenesis","volume":"29","author":"Narayanan","year":"2003","journal-title":"Pediatr Neurol"},{"issue":"4","key":"10.1016\/j.farma.2024.04.023_bb0015","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1080\/09546634.2021.1905768","article-title":"Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence","volume":"33","author":"Cortell Fuster","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"10.1016\/j.farma.2024.04.023_bb0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.12968\/jowc.2003.12.7.26515","article-title":"Exploring the psychosocial concerns of outpatients with disfiguring conditions","volume":"12","author":"Rumsey","year":"2003","journal-title":"J Wound Care"},{"issue":"10","key":"10.1016\/j.farma.2024.04.023_bb0025","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/archdischild-2012-302470","article-title":"The psychosocial impact of an infantile haemangioma on children and their parents","volume":"97","author":"Zweegers","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.farma.2024.04.023_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2016.04.003","article-title":"Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex-a comprehensive review of the literature","volume":"61","author":"J\u00f3\u017awiak","year":"2016","journal-title":"Pediatr Neurol"},{"issue":"6","key":"10.1016\/j.farma.2024.04.023_bb0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ced.12327","article-title":"Treatment of nodular facial angiofibromas in tuberous sclerosis, using ultrapulse carbon dioxide laser","volume":"39","author":"Biondo","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.farma.2024.04.023_bb0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jdv.12665","article-title":"Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"29","author":"Balestri","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.farma.2024.04.023_bb0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs R D"},{"issue":"1","key":"10.1016\/j.farma.2024.04.023_bb0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.farma.2024.04.023_bb0055","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","article-title":"Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the treatment randomized clinical trial","volume":"154","author":"Koenig","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.farma.2024.04.023_bb0060","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/bjd.18949","article-title":"The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial","volume":"183","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.farma.2024.04.023_bb0065","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/bjd\/ljad243","article-title":"A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial","volume":"189","author":"Aitken","year":"2023","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2024.04.023_bb0070","first-page":"A1","article-title":"Physical, chemical, and microbiological stability of sirolimus 0.4% in topical formulations. Abstract Book 24th EAHP Congress Barcelona, Spain; 2019. p. A50","volume":"26","author":"Cortell","year":"2019","journal-title":"EJHP"},{"issue":"1-2","key":"10.1016\/j.farma.2024.04.023_bb0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijpharm.2016.05.064","article-title":"Formulation and characterization of a 0.1% rapamycin cream for the treatment of tuberous sclerosis complex-related angiofibromas","volume":"509","author":"Bougueon","year":"2016","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.farma.2024.04.023_bb0080","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1081\/PDT-100102029","article-title":"Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications","volume":"5","author":"Patel","year":"2000","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.farma.2024.04.023_bb0085","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.2147\/IJN.S216432","article-title":"Intravesical delivery of rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel","volume":"14","author":"Yoon","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.farma.2024.04.023_bb0090","doi-asserted-by":"crossref","DOI":"10.1007\/s12247-023-09792-9","article-title":"Optimization, formulation, and stability of topical rapamycin used for rare tuberous sclerosis disease: from ointment to liposomes","author":"Cortell-Fuster","year":"2023","journal-title":"J Pharmaceut Innov"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2024.04.023_bb0095","first-page":"A1","article-title":"Topical rapamycin in rare tuberous sclerosis disease: liposomal formulation stability. Abstract Book 27th EAHP Congress Lisbon, Portugal; 2023. p. 182","volume":"30","author":"Cortell","year":"2023","journal-title":"Eur J Hosp Pharm"},{"issue":"8","key":"10.1016\/j.farma.2024.04.023_bb0100","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/ced.12398","article-title":"Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma","volume":"39","author":"Salido-Vallejo","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.farma.2024.04.023_bb0105","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ad.2012.11.020","article-title":"Current options for the treatment of facial angiofibromas","volume":"105","author":"Salido-Vallejo","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"11","key":"10.1016\/j.farma.2024.04.023_bb0110","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1021\/mp400362v","article-title":"Sirolimus encapsulated liposomes for cancer therapy: physicochemical and mechanical characterization of sirolimus distribution within liposome bilayers","volume":"10","author":"Onyesom","year":"2013","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.farma.2024.04.023_bb0115","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3109\/08982100902963043","article-title":"Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells","volume":"19","author":"Rouf","year":"2009","journal-title":"J Liposome Res"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:00:52Z","timestamp":1762365652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1130634324000801"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.04.023","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}